Novartis AG (NVS): Price and Financial Metrics
Novartis AG (NVS)
Today's Latest Price: $87.57 USD
Updated Jul 2 7:00pm
Add NVS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVS Stock Summary
- Novartis Ag's market capitalization of $197,825,841,342 is ahead of 99.42% of US-listed equities.
- In terms of volatility of its share price, NVS is more volatile than only 1.36% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVS comes in at 8.56% -- higher than that of 80.07% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Novartis Ag are MRK, PFE, CSCO, NFLX, and DIS.
- NVS's SEC filings can be seen here. And to visit Novartis Ag's official web site, go to www.novartis.com.
NVS Stock Price Chart Technical Analysis Charts
NVS Price/Volume Stats
| Current price | $87.57 | 52-week high | $99.84 |
| Prev. close | $87.85 | 52-week low | $69.18 |
| Day low | $87.39 | Volume | 1,101,452 |
| Day high | $88.07 | Avg. volume | 2,364,362 |
| 50-day MA | $86.52 | Dividend yield | 2.3% |
| 200-day MA | $88.34 | Market Cap | 200.42B |
Novartis AG (NVS) Company Bio
Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.
NVS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $87.57 | $60.75 | -30% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novartis Ag. To summarize, we found that Novartis Ag ranked in the 38th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for NVS, they are:
- The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 24.62% of free cash flow generating stocks in the Healthcare sector.
- NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 35.34% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -32% |
| 1% | -31% |
| 2% | -30% |
| 3% | -30% |
| 4% | -29% |
| 5% | -28% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVS, try HRC, MDT, BDX, USPH, and LCI.
Loading social stream, please wait...